TXA2 mediates LPA1-stimulated uterine contraction in late pregnant mouse
- PMID: 37062326
- DOI: 10.1016/j.prostaglandins.2023.106736
TXA2 mediates LPA1-stimulated uterine contraction in late pregnant mouse
Abstract
Lysophosphatidic acid (LPA) is known to increase uterine contraction in the estrus cycle and early pregnancy, however, the effect of LPA in late pregnant uterus and its mechanisms are not clear. In the present study, we show the LPA receptor subtypes expressed and the mechanism of LPA-induced contractions in late pregnant mouse uterus. We determined the relative mRNA expression of LPA receptor genes by quantitative PCR and elicited log concentration-response curves to oleoyl-L-α-LPA by performing tension experiments in the presence and absence of nonselective and selective receptor antagonists and inhibitors of the TXA2 pathway. LPA1 was the most highly expressed receptor subtype in the late pregnant mouse uterus and LPA1/2/3 agonist (Oleoyl-L-α LPA) elicited increased contractions in this tissue that had lesser efficacy compared to oxytocin. LPA1/3 antagonist, Ki-16425, and a potent LPA1 antagonist (AM-095) significantly inhibited the LPA-induced contractions. Further, the nonselective COX inhibitor, indomethacin, and potent thromboxane A2 synthase inhibitor, furegrelate significantly impaired LPA-induced contractions. Moreover, selective thromboxane receptor (TP) antagonist, SQ-29548, and Rho kinase inhibitor, Y-27632 almost eliminated LPA-induced uterine contractions. LPA1 stimulation elicits contractions in the late pregnant mouse uterus using the contractile prostanoid, TXA2 and may be targeted to induce labor in uterine dysfunctions/ dystocia.
Keywords: Cyclo-oxygenase; LPA1 receptor; Oleoyl-L-α LPA; Rho kinase; Thromboxane A2.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest The authors declare that no conflict of interest could be perceived as prejudicing the impartiality of the research reported.
Similar articles
-
LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction.FASEB J. 2017 Apr;31(4):1547-1555. doi: 10.1096/fj.201600735R. Epub 2017 Jan 9. FASEB J. 2017. PMID: 28069828 Free PMC article.
-
Participation of analogues of lysophosphatidic acid (LPA): oleoyl-sn-glycero-3-phosphate (L-alpha-LPA) and 1-oleoyl-2-O-methyl-rac-glycerophosphothionate (OMPT) in uterine smooth muscle contractility of the pregnant pigs.Pol J Vet Sci. 2012;15(4):635-43. doi: 10.2478/v10181-012-0100-9. Pol J Vet Sci. 2012. PMID: 23390752
-
Lysophosphatidic acid stimulates rat uterine contraction in vitro.J Reprod Dev. 2023 Jun 6;69(3):163-169. doi: 10.1262/jrd.2023-011. Epub 2023 Apr 13. J Reprod Dev. 2023. PMID: 37045747 Free PMC article.
-
GPR87 mediates lysophosphatidic acid-induced colony dispersal in A431 cells.Eur J Pharmacol. 2013 Sep 5;715(1-3):15-20. doi: 10.1016/j.ejphar.2013.06.029. Epub 2013 Jul 4. Eur J Pharmacol. 2013. PMID: 23831392 Review.
-
Stress, Depression, Resilience and Ageing: A Role for the LPA-LPA1 Pathway.Curr Neuropharmacol. 2018 Mar 5;16(3):271-283. doi: 10.2174/1570159X15666170710200352. Curr Neuropharmacol. 2018. PMID: 28699486 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous